Bibliometric analysis of research trends on nanotechnology applications in atherosclerosis
Source abstract
Abstract
Atherosclerosis (AS) is a leading global health issue with limited traditional diagnostic and therapeutic precision. Nanomedicine, utilizing nanomaterials' unique properties, offers promising innovative solutions for atherosclerosis diagnosis and treatment. Studies focusing on nanotechnology and atherosclerosis were retrieved from the Web of Science Core Collection. Relevant articles were selected for inclusion in the study according to the inclusion criteria. Bibliometric analysis of the included publications was performed via VOSviewer, CiteSpace and Bibliometrix. A total of 2682 publications were included in this analysis. From 1999 to 2025, the global academic paper output exhibited a significant upward trend. China, Harvard University, and Scholar Mulder, Willem J M were the most productive country, institution, and author. The International Journal of Nanomedicine was the journal with the highest publication volume. The research on the application of nanotechnology in AS has evolved from investigating disease basic mechanisms to targeted drug delivery therapy and imaging technology, and now to the stage of multi-mechanism collaborative therapy. Future development trends focus on research into extracellular vesicles, biomimetic nanoparticles, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. Relevant research may accelerate cross-integration and provide useful directions for the treatment of atherosclerotic diseases. This bibliometric analysis summarizes the current application status and research hotspots of nanotechnology in atherosclerosis and identifies future application trends. These findings provide valuable insights into the utilization and development directions of nanotechnology in atherosclerosis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: scientometrics and bibliometrics research · Biological Research and Disease Studies · Cancer Research and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (71)
Show source-provided references
1. Bugger H, Zirlik A. Anti-inflammatory strategies in atherosclerosis. Hamostaseologie. 2021;41(6):433–42. https://doi.org/10.1055/a-1661-0020.10.1055/a-1661-0020 ↗
2. Xu R, Wang Z, Dong J, Yu M, Zhou Y. Lipoprotein(a) and panvascular disease. Lipids Health Dis. 2025;24(1):186. https://doi.org/10.1186/s12944-025-02600-y.10.1186/s12944-025-02600-y ↗
3. Baumer Y, Irei J, Boisvert WA. Cholesterol crystals in the pathogenesis of atherosclerosis. Nat Rev Cardiol. 2025;22(5):315–32. https://doi.org/10.1038/s41569-024-01100-3.10.1038/s41569-024-01100-3 ↗
4. Liu F, Wang Y, Yu J. Role of inflammation and immune response in atherosclerosis: mechanisms, modulations, and therapeutic targets. Hum Immunol. 2023;84(9):439–49. https://doi.org/10.1016/j.humimm.2023.06.002.10.1016/j.humimm.2023.06.002 ↗
5. Violi F, Pastori D, Pignatelli P, Carnevale R. Nutrition, Thrombosis, and Cardiovascular Disease. Circ Res. 2020;126(10):1415–42. https://doi.org/10.1161/CIRCRESAHA.120.315892.10.1161/CIRCRESAHA.120.315892 ↗
6. Hou XZ, Yang YT, Yao JM. Vulnerable plaques in atherosclerosis: focus on angiogenesis-associated phenotypic crosstalk. Front Pharmacol. 2026;16:1737140. https://doi.org/10.3389/fphar.2025.1737140.10.3389/fphar.2025.1737140 ↗
7. Liu Y, Zhang X, Yu L, Cao L, Zhang J, Li Q, et al. E3 ubiquitin ligase RNF128 promotes Lys63-linked polyubiquitination on SRB1 in macrophages and aggravates atherosclerosis. Nat Commun. 2025;16(1):2185. https://doi.org/10.1038/s41467-025-57404-6.10.1038/s41467-025-57404-6 ↗
8. Cheng G, Liu J, Zhang H, Cui Y, Xu S, Wang L. Sortilin as a Culprit in the atherosclerosis plaque progression: evidence from clinical and experimental studies. Curr Mol Med. 2025;25(10):1259–68. https://doi.org/10.2174/0115665240342078250114165535.10.2174/0115665240342078250114165535 ↗
9. Professional Group of Lipid and Atherosclerosis, Cardiovascular Disease Committee of Chinese Association of the Integration of Traditional Chinese and Western Medicine. Expert consensus on the diagnosis and treatment of atherosclerosis by combination of traditional chinese and western medicine. Chin Gen Pract. 2017;20(5):507–11. https://doi.org/10.3969/j.issn.1007-9572.2017.01.y03.10.3969/j.issn.1007-9572.2017.01.y03 ↗
10. Global Burden of Cardiovascular Diseases and Risks. 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J Am Coll Cardiol. 2025;86(22):2167–2243. https://doi.org/10.1016/j.jacc.2025.08.01510.1016/j.jacc.2025.08.015 ↗
11. Stroke 2019 GBD, Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. https://doi.org/10.1016/S1474-4422(21)00252-0.10.1016/S1474-4422(21)00252-0 ↗
12. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021;73(3):924–67. https://doi.org/10.1124/pharmrev.120.000096.10.1124/pharmrev.120.000096 ↗
13. Gu X, Du L, Lin R, Ding Z, Guo Z, Wei J, et al. How Advanced Is Nanomedicine for Atherosclerosis? Int J Nanomed. 2025;20:3445–70. https://doi.org/10.2147/IJN.S508757.10.2147/IJN.S508757 ↗
14. Jiang HY, Shao B, Wang HD, Zhao WQ, Ren SH, Xu YN, et al. Analysis of nanomedicine applications for inflammatory bowel disease: structural and temporal dynamics, research hotspots, and emerging trends. Front Pharmacol. 2025;15:1523052. https://doi.org/10.3389/fphar.2024.1523052.10.3389/fphar.2024.1523052 ↗
15. Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018;9:1050–74. https://doi.org/10.3762/bjnano.9.98.10.3762/bjnano.9.98 ↗
16. Cai J, Ge X, Lu S, Wang Y, Cui H, Zhan R, et al Au/FeNiPO4-Based multiple spectra optoacoustic tomography/CT dual‐mode nanoprobe for systemic screening of atherosclerotic vulnerable plaque. Adv Funct Mater. 2024;34(44):2406192. https://doi.org/10.1002/adfm.202406192.10.1002/adfm.202406192 ↗
17. Kosuge H, Nakamura M, Oyane A, Tajiri K, Murakoshi N, Sakai S, et al. Potential of gold nanoparticles for noninvasive imaging and therapy for vascular inflammation. Mol Imaging Biol. 2022;24(5):692–9. https://doi.org/10.1007/s11307-021-01654-5.10.1007/s11307-021-01654-5 ↗
18. Lv W, Liu Y, Li S, Lv L, Lu H, Xin H. Advances of nano drug delivery system for the theranostics of ischemic stroke. J Nanobiotechnol. 2022;20(1):248. https://doi.org/10.1186/s12951-022-01450-5.10.1186/s12951-022-01450-5 ↗
19. Li B, Shao H, Gao L, Li H, Sheng H, Zhu L. Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv. 2022;29(1):2130–61. https://doi.org/10.1080/10717544.2022.2127213.10.1080/10717544.2022.2127213 ↗
20. Rai S, Singh N, Bhattacharya S. Concepts on Smart Nano-Based Drug Delivery System. Recent Pat Nanotechnol. 2022;16(1):67–89. https://doi.org/10.2174/1872210515666210120113738.10.2174/1872210515666210120113738 ↗
21. Huang L, Huang XH, Yang X, Hu JQ, Zhu YZ, Yan PY, et al. Novel nano-drug delivery system for natural products and their application. Pharmacol Res. 2024;201:107100. https://doi.org/10.1016/j.phrs.2024.107100.10.1016/j.phrs.2024.107100 ↗
22. Jiang T, Xu L, Zhao M, Kong F, Lu X, Tang C, et al. Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy. Biomaterials. 2022;280:121324. https://doi.org/10.1016/j.biomaterials.2021.121324.10.1016/j.biomaterials.2021.121324 ↗
23. Jiang X, Ma C, Gao Y, Cui H, Zheng Y, Li J, et al. Tongxinluo attenuates atherosclerosis by inhibiting ROS/NLRP3/caspase-1-mediated endothelial cell pyroptosis. J Ethnopharmacol. 2023;304:116011. https://doi.org/10.1016/j.jep.2022.116011.10.1016/j.jep.2022.116011 ↗
24. Jiang M, Zhu Z, Zhou Z, Yan Z, Huang K, Jiang R, et al. A temperature-ultrasound sensitive nanoparticle delivery system for exploring central neuroinflammation mechanism in stroke-heart syndrome. J Nanobiotechnol. 2024;22(1):681. https://doi.org/10.1186/s12951-024-02961-z.10.1186/s12951-024-02961-z ↗
25. Zhu X, Lv M, Cheng T, Zhou Y, Yuan G, Chu Y, et al. Bibliometric analysis of atrial fibrillation and ion channels. Heart Rhythm. 2024;21(7):1161–9. https://doi.org/10.1016/j.hrthm.2024.01.032.10.1016/j.hrthm.2024.01.032 ↗
26. Chen C, CiteSpace II. Detecting and Visualizing Emerging Trends. J Am Soc Inform Sci Technol. 2006;57(3):359–77. https://doi.org/10.1002/asi.20317.10.1002/asi.20317 ↗
27. Pei Z, Chen S, Ding L, Liu J, Cui X, Li F et al. Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis. J Control Release. 2022;352:211–41. https://doi.org/10.1016/j.jconrel.2022.10.02310.1016/j.jconrel.2022.10.023 ↗
28. Liao F, Germain F, Ma L, Wei C, Wang T. Scientometric analysis of extracellular vesicles in vision science (up to 2024). J Nanobiotechnol. 2025;23(1):654. https://doi.org/10.1186/s12951-025-03703-5.10.1186/s12951-025-03703-5 ↗
29. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. https://doi.org/10.1007/s11192-009-0146-3.10.1007/s11192-009-0146-3 ↗
30. Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetrics. 2018;11(4):959–75. https://doi.org/10.1016/j.joi.2017.08.007.10.1016/j.joi.2017.08.007 ↗
31. Poly TN, Islam MM, Walther BA, Lin MC, Jack Li YC. Artificial intelligence in diabetic retinopathy: bibliometric analysis. Comput Methods Programs Biomed. 2023;231:107358. https://doi.org/10.1016/j.cmpb.2023.107358.10.1016/j.cmpb.2023.107358 ↗
32. Mulder WJ, Cormode DP, Hak S, Lobatto ME, Silvera S, Fayad ZA. Multimodality nanotracers for cardiovascular applications. Nat Clin Pract Cardiovasc Med. 2008;5(Suppl 2):S103–11. https://doi.org/10.1038/ncpcardio1242.10.1038/ncpcardio1242 ↗
33. Priem B, Tian C, Tang J, Zhao Y, Mulder WJ. Fluorescent nanoparticles for the accurate detection of drug delivery. Expert Opin Drug Deliv. 2015;12(12):1881–94. https://doi.org/10.1517/17425247.2015.1074567.10.1517/17425247.2015.1074567 ↗
34. Mulder WJM, van Leent MMT, Lameijer M, Fisher EA, Fayad ZA, Pérez-Medina C. High-Density Lipoprotein Nanobiologics for Precision Medicine. Acc Chem Res. 2018;51(1):127–37. https://doi.org/10.1021/acs.accounts.7b00339.10.1021/acs.accounts.7b00339 ↗
35. Bernal A, Calcagno C, Mulder WJM, Pérez-Medina C. Imaging-guided nanomedicine development. Curr Opin Chem Biol. 2021;63:78–85. https://doi.org/10.1016/j.cbpa.2021.01.014.10.1016/j.cbpa.2021.01.014 ↗
36. Mulder WJ, Griffioen AW, Strijkers GJ, Cormode DP, Nicolay K, Fayad ZA. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomed (Lond). 2007;2(3):307–24. https://doi.org/10.2217/17435889.2.3.307.10.2217/17435889.2.3.307 ↗
37. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;17(11):1241–51. . https://doi.org/10.1016/j.addr.2008.03.01410.1016/j.addr.2008.03.014 ↗
38. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33. https://doi.org/10.1038/s41586-021-03392-8.10.1038/s41586-021-03392-8 ↗
39. Gao C, Huang Q, Liu C, Kwong CHT, Yue L, Wan JB, et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun. 2020;11(1):2622. https://doi.org/10.1038/s41467-020-16439-7.10.1038/s41467-020-16439-7 ↗
40. Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, et al. Knowledge mapping of exosomes in autoimmune diseases: a bibliometric analysis (2002–2021). Front Immunol. 2022;13:939433. https://doi.org/10.3389/fimmu.2022.939433.10.3389/fimmu.2022.939433 ↗
41. Björkegren JLM, Lusis AJ, Atherosclerosis. Recent developments. Cell. 2022;185(10):1630–45. https://doi.org/10.1016/j.cell.2022.04.004.10.1016/j.cell.2022.04.004 ↗
42. Ding C, Min J, Tan Y, Zheng L, Ma R, Zhao R, et al. Combating atherosclerosis with chirality/phase dual-engineered nanozyme featuring microenvironment-programmed senolytic and senomorphic actions. Adv Mater. 2024;36(29):e2401361. https://doi.org/10.1002/adma.202401361.10.1002/adma.202401361 ↗
43. Ding H, Liu Y, Xia T, Zhang H, Hao Y, Liu B, et al. Biomimetic membrane-coated nanoparticles for targeted synergistic therapy of homocysteine-induced atherosclerosis: dual modulation of cholesterol efflux and reactive oxygen species scavenging. Mater Today Bio. 2025;33:101938. https://doi.org/10.1016/j.mtbio.2025.101938.10.1016/j.mtbio.2025.101938 ↗
44. Fu E, Pan K, Li Z. Engineering extracellular vesicles for targeted therapeutics in cardiovascular disease. Front Cardiovasc Med. 2024;11:1503830. https://doi.org/10.3389/fcvm.2024.1503830.10.3389/fcvm.2024.1503830 ↗
45. Aili T, Zong JB, Zhou YF, Liu YX, Yang XL, Hu B, et al. Recent advances of self-assembled nanoparticles in the diagnosis and treatment of atherosclerosis. Theranostics. 2024;14(19):7505–33. https://doi.org/10.7150/thno.100388.10.7150/thno.100388 ↗
46. Rumanti AP, Maruf A, Liu H, Ge S, Lei D, Wang G. Engineered bioresponsive nanotherapeutics: recent advances in the treatment of atherosclerosis and ischemic-related disease. J Mater Chem B. 2021;9(24):4804–25. https://doi.org/10.1039/d1tb00330e.10.1039/d1tb00330e ↗
47. Chen S, Wang Z, Shen Z, He D, Liu L, Qian L, et al. Luteolin nanomedicine with stimulus-driven traceless release for targeting treatment of atherosclerosis by enhancing lipid efflux. Res (Wash D C). 2025;8:0754. https://doi.org/10.34133/research.0754.10.34133/research.0754 ↗
48. Wang L, Zhang X, Zhang H, Wang X, Ren X, Bian W, et al. Novel metal-free nanozyme for targeted imaging and inhibition of atherosclerosis via macrophage autophagy activation to prevent vulnerable plaque formation and rupture. ACS Appl Mater Interfaces. 2024;16(39):51944–56. https://doi.org/10.1021/acsami.4c08671.10.1021/acsami.4c08671 ↗
49. Tian Z, Wang X, Han T, Wang M, Ning H, Sun C. Inhibition of MAOB Ameliorated High-Fat-Diet-Induced Atherosclerosis by Inhibiting Endothelial Dysfunction and Modulating Gut Microbiota. Nutrients. 2023;15(11):2542. https://doi.org/10.3390/nu15112542.10.3390/nu15112542 ↗
50. Sedding DG, Boyle EC, Demandt JAF, Sluimer JC, Dutzmann J, Haverich A, et al. Vasa vasorum angiogenesis: key player in the initiation and progression of atherosclerosis and potential target for the treatment of cardiovascular disease. Front Immunol. 2018;9:706. https://doi.org/10.3389/fimmu.2018.00706.10.3389/fimmu.2018.00706 ↗
51. Hernando-Redondo J, Niño OC, Fitó M. Atherogenic low-density lipoprotein and cardiovascular risk. Curr Opin Lipidol. 2025;36(1):8–13. https://doi.org/10.1097/MOL.0000000000000963.10.1097/MOL.0000000000000963 ↗
52. Wang X, Chen X, Ji H, Han A, Wu C, Jiang J, et al. Dual-Responsive methotrexate-human serum albumin complex-encapsulated liposomes for targeted and enhanced atherosclerosis therapy. Int J Nanomed. 2025;20:2305–22. https://doi.org/10.2147/IJN.S502850.10.2147/IJN.S502850 ↗
53. Ni H, Zhou H, Liang X, Ge Y, Chen H, Liu J, et al. Reactive Oxygen Species-Responsive Nanoparticle Delivery of Small Interfering Ribonucleic Acid Targeting Olfactory Receptor 2 for Atherosclerosis Theranostics. ACS Nano. 2024;18(34):23599–614. https://doi.org/10.1021/acsnano.4c07988.10.1021/acsnano.4c07988 ↗
54. Obaid EAMS, Wu S, Zhong Y, Yan M, Zhu L, Li B, et al. pH-Responsive hyaluronic acid-enveloped ZIF-8 nanoparticles for anti-atherosclerosis therapy. Biomater Sci. 2022;10(17):4837–47. https://doi.org/10.1039/d2bm00603k.10.1039/d2bm00603k ↗
55. Zhang R, Lu K, Xiao L, Hu X, Cai W, Liu L, et al. Exploring atherosclerosis imaging with contrast-enhanced MRI using PEGylated ultrasmall iron oxide nanoparticles. Front Bioeng Biotechnol. 2023;11:1279446. https://doi.org/10.3389/fbioe.2023.1279446.10.3389/fbioe.2023.1279446 ↗
56. Segers FME, Ruder AV, Westra MM, Lammers T, Dadfar SM, Roemhild K. Magnetic resonance imaging contrast-enhancement with superparamagnetic iron oxide nanoparticles amplifies macrophage foam cell apoptosis in human and murine atherosclerosis. Cardiovasc Res. 2023;118(17):3346–59. https://doi.org/10.1093/cvr/cvac032.10.1093/cvr/cvac032 ↗
57. Nankivell VA, Sandeman L, Stretton L, Vidanapathirana AK, Rajora MA, Chen J, et al. Theranostic porphyrin nanoparticles identify atherosclerosis via multimodal imaging and elicit atheroprotective effects. Mater Today Bio. 2025;34:102202. https://doi.org/10.1016/j.mtbio.2025.102202.10.1016/j.mtbio.2025.102202 ↗
58. Overchuk M, Weersink RA, Wilson BC, Zheng G. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine. ACS Nano. 2023;17(9):7979–8003. https://doi.org/10.1021/acsnano.3c00891.10.1021/acsnano.3c00891 ↗
59. Mytych W, Bartusik-Aebisher D, Łoś A, Dynarowicz K, Myśliwiec A, Aebisher D. Photodynamic therapy for atherosclerosis. Int J Mol Sci. 2024;25(4):1958. https://doi.org/10.3390/ijms25041958.10.3390/ijms25041958 ↗
60. Peng M, Liu X, Xu G. Extracellular vesicles as messengers in atherosclerosis. J Cardiovasc Transl Res. 2020;13(2):121–30. https://doi.org/10.1007/s12265-019-09923-z.10.1007/s12265-019-09923-z ↗
61. Bartusik-Aebisher D, Podgórski R, Serafin I, Aebisher D. Targeted and biomimetic nanoparticles for atherosclerosis therapy: a review of emerging strategies. Biomedicines. 2025;13(7):1720. https://doi.org/10.3390/biomedicines13071720.10.3390/biomedicines13071720 ↗
62. Shao BZ, Xu HY, Zhao YC, Zheng XR, Wang F, Zhao GR. NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation. Inflammation. 2023;46(1):35–46. https://doi.org/10.1007/s10753-022-01725-x.10.1007/s10753-022-01725-x ↗
63. Najahi-Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: Are we there yet? Int J Mol Sci. 2020;22(1):385. https://doi.org/10.3390/ijms22010385.10.3390/ijms22010385 ↗
64. Cheng TM, Chu HY, Huang HM, Li ZL, Chen CY, Shih YJ, et al. Toxicologic concerns with current medical nanoparticles. Int J Mol Sci. 2022;23(14):7597. https://doi.org/10.3390/ijms23147597.10.3390/ijms23147597 ↗
65. Missaoui WN, Arnold RD, Cummings BS. Toxicological status of nanoparticles: what we know and what we don’t know. Chem Biol Interact. 2018;295:1–12. https://doi.org/10.1016/j.cbi.2018.07.015.10.1016/j.cbi.2018.07.015 ↗
66. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023;12(30):e2301956. https://doi.org/10.1002/adhm.202301956.10.1002/adhm.202301956 ↗
67. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653–64. https://doi.org/10.1039/d0bm00558d.10.1039/d0bm00558d ↗
68. Allan J, Belz S, Hoeveler A, Hugas M, Okuda H, Patri A. Regulatory landscape of nanotechnology and nanoplastics from a global perspective. Regul Toxicol Pharmacol. 2021;122:104885. https://doi.org/10.1016/j.yrtph.2021.104885.10.1016/j.yrtph.2021.104885 ↗
69. Sainz V, Conniot J, Matos AI, Peres C, Zupancic E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468(3):504–10. https://doi.org/10.1016/j.bbrc.2015.08.023.10.1016/j.bbrc.2015.08.023 ↗
70. Soares S, Sousa J, Pais A, Vitorino C, Nanomedicine. principles, properties, and regulatory issues. Front Chem. 2018;6:360. https://doi.org/10.3389/fchem.2018.00360.10.3389/fchem.2018.00360 ↗
71. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500–25. https://doi.org/10.1007/s13346-021-01024-2.10.1007/s13346-021-01024-2 ↗